Download Files:
Monlunabant
SKU
HY-153800-10 mg
Category Reference compound
Tags Cannabinoid Receptor, GPCR/G Protein;Neuronal Signaling, Neurological Disease
$480 – $4,000
Products Details
Product Description
– Monlunabant ((S)-MRI-1891) is a solid dispersions compound, as well as a cannabinoid CB1 receptor inhibitor[1].
Web ID
– HY-153800
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C26H22ClF3N6O3S
References
– [1]Liu Z, Iyer MR, Godlewski G, Jourdan T, Liu J, Coffey NJ, Zawatsky CN, Puhl HL, Wess J, Meister J, Liow JS, Innis RB, Hassan SA, Lee YS, Kunos G, Cinar R. Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB1R) Antagonist. ACS Pharmacol Transl Sci. 2021 Apr 8;4(3):1175-1187.
CAS Number
– 2712480-46-9
Molecular Weight
– 591.00
Compound Purity
– 99.89
SMILES
– O=S(N/C(N1N=C(C2=CC=C(C=C2)Cl)[C@@H](C3=CC=CC=C3)C1)=N/C(NC(C)=O)=N)(C4=CC=C(C=C4)C(F)(F)F)=O
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– 10 mM in DMSO
Target
– Cannabinoid Receptor
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.